Wedbush initiated coverage on Albireo Pharma with a new price target
$ALBO
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush initiated coverage of Albireo Pharma with a rating of Outperform and set a new price target of $75.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/9/2023 | $53.00 → $42.00 | Outperform → Neutral | Wedbush |
9/8/2022 | $55.00 | Buy | Guggenheim |
3/28/2022 | $75.00 | Outperform | Wedbush |
11/5/2021 | $79.00 → $80.00 | Buy | HC Wainwright & Co. |
9/16/2021 | $82.00 → $84.00 | Outperform | Wedbush |
7/21/2021 | $73.00 → $82.00 | Outperform | Wedbush |